Participation of renal and circulating endothelin in salt-sensitive essential hypertension
- PMID: 12080429
- DOI: 10.1038/sj.jhh.1001419
Participation of renal and circulating endothelin in salt-sensitive essential hypertension
Abstract
Salt sensitivity of blood pressure is a cardiovascular risk factor, independent of and in addition to hypertension. In essential hypertension, a conglomerate of clinical and biochemical characteristics defines a salt-sensitive phenotype. Despite extensive research on multiple natriuretic and antinatriuretic systems, there is no definitive answer yet about the major causes of salt-sensitivity, probably reflecting the complexity of salt-balance regulation. The endothelins, ubiquitous peptides first described as potent vasoconstrictors, also have vasodilator, natriuretic and antinatriuretic actions, depending on their site of generation and binding to different receptors. We review the available data on endothelin in salt-sensitive essential hypertension and conclude that abnormalities of renal endothelin may play a primary role. More importantly, the salt-sensitive patient may have blood pressure-dependency on endothelin in all states of salt balance, thus predicting that endothelin receptor blockers will have a major therapeutic role in salt-sensitive essential hypertension.
Similar articles
-
Role of endothelins in hypertension.Am J Ther. 2007 Mar-Apr;14(2):147-53. doi: 10.1097/01.pap.0000249912.02763.65. Am J Ther. 2007. PMID: 17414582 Review.
-
Endothelin in hypertension.Curr Opin Cardiol. 1995 Sep;10(5):485-94. Curr Opin Cardiol. 1995. PMID: 7496057 Review.
-
[Salt-sensitive hypertension].Arch Cardiol Mex. 2006 Apr-Jun;76 Suppl 2:S161-3. Arch Cardiol Mex. 2006. PMID: 17017093 Review. Spanish.
-
Pathophysiological mechanisms of salt-dependent hypertension.Am J Kidney Dis. 2007 Oct;50(4):655-72. doi: 10.1053/j.ajkd.2007.05.025. Am J Kidney Dis. 2007. PMID: 17900467 Review.
-
Vascular endothelin in hypertension.Vascul Pharmacol. 2005 Jun;43(1):19-29. doi: 10.1016/j.vph.2005.03.004. Vascul Pharmacol. 2005. PMID: 15955745 Review.
Cited by
-
TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats.Int J Hypertens. 2011;2011:751513. doi: 10.4061/2011/751513. Epub 2011 Dec 22. Int J Hypertens. 2011. PMID: 22235363 Free PMC article.
-
The future of endothelin-receptor antagonism as treatment for systemic hypertension.Curr Hypertens Rep. 2006 Apr;8(1):35-44. doi: 10.1007/s11906-006-0039-2. Curr Hypertens Rep. 2006. PMID: 16600158 Review.
-
Role of 20-hydroxyeicosatetraenoic acid in mediating hypertension in response to chronic renal medullary endothelin type B receptor blockade.PLoS One. 2011;6(10):e26063. doi: 10.1371/journal.pone.0026063. Epub 2011 Oct 7. PLoS One. 2011. PMID: 22016812 Free PMC article.
-
A potential role for the endothelin ETA receptor in salt-sensitive hypertension of the proANP gene-disrupted mouse.Mol Cell Biochem. 2005 Jul;275(1-2):57-66. doi: 10.1007/s11010-005-7716-3. Mol Cell Biochem. 2005. PMID: 16335784
-
Inflammation and therapy for hypertension.Curr Hypertens Rep. 2010 Aug;12(4):233-42. doi: 10.1007/s11906-010-0125-3. Curr Hypertens Rep. 2010. PMID: 20524088 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical